Case report of a combined oncocytoma and type 1 papillary renal cell carcinoma: a rare entity

R. Gaeta1, A. Tognetti2, E.F. Kauffmann3, L.E. Pollina2

1 Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa, Italy; 2 U.O. Pathological Anatomy II, Pisa University Hospital, Italy; 3 Division of General and Transplant Surgery, University of Pisa, Italy

Introduction

According to the World Health Organization, kidney cancer is the ninth most common cancer in men and the fourteenth most common in women worldwide, but the sixteenth most common cause of death from cancer for both gender 1. Among these, Renal Cell Carcinoma (RCC) is the most frequent type of kidney cancer in adults (average age at diagnosis 55 to 60 years) 2, responsible for approximately 90-95% of cases 3. The second most common histologic variant of RCC (10-15%) is the Papillary Type (PRCC) 4, a malignant tumor derived from renal tubular epithelium. It is usually a well circumscribed papillary or tubulo-papillary cancer which occurs in the renal cortex and might be related to end-stage renal disease or acquired cystic disease 4. Two subtypes are recognized: type 1 tumours, composed by papillae covered by a single layer of small uniform cells; type 2 tumours, characterized by pseudostratified cells with eosinophilic cytoplasm and high nuclear grade covering the papillae 4. Renal Oncocytoma (RO) is a benign epithelial tumor of the intercalated cells of collecting tubules 5 and is composed by uniform round or polygonal cells with abundant, intensely eosinophilic and granular cytoplasm. It represents 4-7% of adult renal epithelial tumors (mean age 62 years) and it is usually incidental 6. Hybrid tumor composed of PRCC and RO within the same tumor is extremely rare, in fact, there are only eight cases documented in the literature 7. The second...
case of intimately mixed RO and PRCC in a single mass is described in this article. Our patient is the youngest among the previous reports being 44.

**Case report**

A 44-year-old man with history of hiatal hernia and gastroesophageal reflux disease presented to the hospital emergency department due to asthenia, nausea, fever, jaundice, hyperchromic urine and hypochromic faeces caused by HBV. Abdominal ultrasound performed to investigate the symptoms incidentally identified a solid exophytic mass in the lower left renal pole. Subsequent Computed tomography (CT) with Contrast Media (Visipaque 320) disclosed that the neoplasm was 3.5 x 2.0 cm in size with 3.8 cm longitudinal diameter with non-homogeneous contrast enhancement, compatible with a solid cortical tumor (Fig. 1 a-c).

According to the well-consolidated concept of the nephron sparing surgery in case of suspected RCC, the patient underwent Robot-Assisted Enucleation of the tumour with preoperative placement of ureteral stent in order to prevent post-operative urinous fistula due to the proximity of the neoplasm to the calices.

**Macroscopical, histological and immunohistochemical results**

Gross examination revealed a 3.5 x 2.5 x 2.5 cm well-capsulated mahogany to dark brown solid mass with focal haemorrhagic areas. At haematoxylin and eosin staining, areas with tubulo-papillary structures made up with small cells with scanty cytoplasm, arranged in a single layer on the papillary basement membrane were observed. Nuclei showed finely granular “open” chromatin; nucleoli at 100X were small and inconspicuous while appeared well visible and eosinophilic at 400X. Diffuse haemorrhage was present. The appearances were those of a type 1, papillary renal cell carcinoma, Fuhrman nuclear grade 2. Adjacent to this neoplasm, polygonal cells forming solid sheet and tubules with abundant eosinophilic cytoplasm and uniform, round central nuclei without mitoses have been observed. The morphology was compatible with the diagnosis of oncocytoma. Contrary to previous cases of hybrid renal cancer reported in literature, no pseudocapsule divided the two histotypes of tumors (Fig. 2).

Surgical margins were free of tumor and there was no extra capsular tumor infiltration into perinephric fat tissue. According to the American Joint Committee on
CASE REPORT OF A COMBINED ONCOCYTOMA AND TYPE 1 PAPILLARY RENAL CELL CARCINOMA: A RARE ENTITY

Cancer (AJCC) classification, the tumour was staged as T1aN0MX.

Immunohistochemical staining revealed a heterogeneous profile. The papillary component of the neoplasia showed the typical panel of the PRCC, i.e. positivity for CK7, vimentin, BerEP4 and a weak positivity for CD10, instead the oncocytoma areas were positive for CD117 and negative for the cytokeratines, vimentin and CD10 (Fig. 3 a-b).

Immunohistochemical panel used in the study is summarized in Table I.

**Tab. I.** Immunohistochemical panel used in the study.

<table>
<thead>
<tr>
<th></th>
<th>Papillary Renal Cell Carcinoma</th>
<th>Renal Oncocytoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cytokeratine 7</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>Vimentin</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>CD10</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>BerEP4</td>
<td>Positive</td>
<td>Negative</td>
</tr>
<tr>
<td>CD117</td>
<td>Negative</td>
<td>Positive</td>
</tr>
</tbody>
</table>

Discussion and conclusions

“Collision tumors” refers to coexistent but histologically distinct tumors that result from two separate but adjacent neoplasm. In the kidney, collision tumours have been previously described, however they were mainly composed of oncocytoma and chromophobe renal cell carcinoma (ChRCC). They are seen in three settings, namely Birt-Hogg-Dubé Syndrome, renal oncocytosis, and as sporadic neoplasia. Mixed renal tumours composed of a component other than ChRCC in addition to oncocytoma are unusual. In particular, combined oncocytoma-PRCC is extremely rare.

There are no evidences suggesting a relation between oncocytoma and papillary RCC since they originate from different cells. PRCC derives from proximal or distal convoluted tubule, while oncocytoma arises from distal nephron, probably from the epithelium of the collecting tubule.

Given the possibility of oncocytomas to harbour other tumours, we suggest, particularly in large oncocytomas, careful examination of the samples to exclude the presence of an associated malignant neoplasm, which might have a significantly worse prognosis than oncocytoma. A differential diagnosis is needed since the prognosis of the two histotypes changes critically. Sporadic oncocytomas are benign neoplasm with an excellent prognosis: they typically do not recur after surgical treatment and the lifespan of affected people is usually not impacted by the tumour.

Papillary RCC is a malignant tumour whose prognosis strictly depends upon a set of several factors, which include the histomorphology (e.g. mitosis, necrosis), the stage, the surgical respectability of the tumour, the age of the individual and the response to treatment. Immuno-histochemical stains is of great help in distinguishing the two components.

In literature, only eight cases of combined oncocytoma-PRCC have been reported. The literature is summarized in Table I.

**Fig. 3. a-b)** Immunohistochemistry of the two different constituents within the tumor: CK7 and Vimentin are positive in papillary RCC, but negative in oncocytoma (a. CK7, 40X; b. anti-vimentin, 100X).
toma-PRCC are described 7 11-18. Previously reported cases showed that the PRCC component within the oncocytoma was well delineated and distinct on both gross and microscopic examination. Our case differs from the others since the PRCC area is not well shaped, but is closely intermingled to the oncocytoma. By comparing the previous cases, there is an evident prevalence for male since only one combined oncocytoma-PRCC in female is described 16. Type 1 and type 2 PRCC show an equal percentage of incidence (50%). Moreover, our patient is the youngest among the previous reports being 44. New cases of combined oncocytoma-PRCC tumours could provide additional information useful for optimal treatment policy that can have a strong impact on the prognosis of affected patients.

CONFLICT OF INTEREST STATEMENT
None declared.

References

Received: July 12, 2018 - Accepted: February 26, 2019